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Abstract
Complement fragment C3d covalently attached to antigens enhances immune responses, 
particularly for antigens lacking T cell epitopes. Enhancement has been attributed to receptor 
cross-linking between complement receptor CR2 (CD21) and polysaccharide antigen to surface 
IgM on naïve B cells. Paradoxically, C3d has still been shown to increase immune responses in 
CD21 KO mice, suggesting that an auxiliary activation pathway exists. In prior studies, we 
demonstrated the CD21-independent C3d adjuvant effect might be due to T cell recognition of 
C3d T helper epitopes processed and presented by MHC class II on the B cell surface. C3d peptide 
sequences containing concentrated clusters of putative human C3 T cell epitopes were identified 
using the epitope-mapping algorithm, EpiMatrix. These peptide sequences were synthesized and 
shown in vitro to bind multiple HLA-DR alleles with high affinity, and induce IFNγ responses in 
healthy donor PBMCs. In the present studies, we establish further correlations between HLA 
binding and HLA-specific lymphocyte reactions with select epitope clusters. Additionally, we 
show that the T cell phenotype of C3d-specific reactive T cells is CD4+CD45RO+ memory T 
cells. Finally, mutation of a single T cell epitope residing within the P28 peptide segment of C3d 
resulted in significantly diminished adjuvant activity in BALB/c mice. Collectively, these studies 
support the hypothesis that the paradoxical enhancement of immune responses by C3d in the 
absence of CD21 is due to internalization and processing of C3d into peptides that activate 
autoreactive CD4+ T helper cells in the context of HLA class II.
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INTRODUCTION
Two methods of adjuvant conjugation to antigen have been shown to greatly improve the 
efficacy of polysaccharide vaccines: use of an immunogenic foreign T cell epitope-rich 
protein, and use of complement fragment C3d.1–3 The adjuvant effect of C3d is said to result 
from the synergistic effect of two events: (1) polysaccharide antigen binding to the IgM/D B 
cell receptor, and (2) C3d binding to the B cell complement receptor 2 (CR2 or CD21). The 
co-activation of these two signals has been shown to lower the threshold of activation and to 
promote a more robust immune response by inducing isotype switching, somatic 
hypermutation, and B cell memory generation.4 Yet in mice lacking complement receptors 
CR1 (CD35) and CR2 (CD21), immune responses to protein antigen-C3d conjugates were 
equally enhanced to the levels seen in wild-type mice.5–7 Further, C3−/− mice, but not 
CD21−/− have been shown to be deficient in T dependent responses.8 These findings 
suggest that the current model for C3d activity may be incomplete and an auxiliary immune 
activation pathway exists.
We have hypothesized that in addition to its molecular adjuvant property enhancing signal 1 
in antigen-specific B cell activation, C3d also contains T cell epitopes that stimulate 
autoreactive C3d peptide-specific T helper cells, creating a response similar to that of any 
cognate T helper epitope.9 Multiple repeats of polysaccharide residues can cause cross-
linking of antibody regions and internalization of the conjugate into the B cell antigen 
processing compartments. Processing and presentation of any protein components associated 
with the polysaccharide antigen that bind to MHC will ensue: the resulting peptide-
associated MHC II complexes presented on the B cell surface generate help by activating 
CD4+ T cells via recognition of T cell antigen receptors. This induction of T-dependent (Td) 
responses may result in the generation of T cell help for any anti-polysaccharide B cell 
responses, generating higher antibody titers and higher affinity antibodies than T-
independent (Ti) responses.
In previous studies, we used the EpiMatrix algorithm to identify T cell epitopes in 
complement C3 and assessed their binding potential to multiple HLA haplotypes.9 We 
determined that the frequency of putative T cell epitopes in complement C3 was greater than 
many other human plasma proteins analyzed using the EpiMatrix algorithm. Further, the 
distribution of these putative T helper epitopes within C3 was non-uniform and concentrated 
within the C3d segment. Thus, we have postulated that the previously-observed 
enhancement of the immune response by C3 might be due in part to the activation of C3d 
peptide-specific autoreactive T helper cells. This discovery of T cell epitopes within C3d 
offers a novel explanation for the adjuvant effect of C3d and a potential resolution of the 
paradoxical results observed in CD21 KO mice.
Here, we examine three putative T cell epitope “clusters” from C3d that were identified in 
earlier studies.9 In vitro HLA binding studies and ex vivo PBMC responses from four 
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separate HLA-typed donors correlated with epitope mapping predictions. Further, ex vivo 
PBMC responses to C3d peptides were found to be associated with a CD4+CD45RO
+population of memory T cells, suggesting that C3d-specific T cells are autoreactive 
memory T cells. Finally, the contribution of T cell epitope-mediated immunogenicity to C3d 
activity was confirmed by mutation of the single predicted T cell epitope in the P28 peptide 
segment of C3d expected to reduce binding to murine MHC. In immunization studies, T cell 
responses to hapten-conjugated C3d mutants were diminished, further supporting the 
contribution of autoreactive T helper responses to the adjuvant activity of the C3d fragment 
of C3.
RESULTS
Epitope analysis and peptide synthesis
Candidate T cell epitopes in C3 were identified using the EpiMatrix algorithm as described 
in Methods and reference 9. Within the 302-amino acid C3d sequence, 11 putative T cell 
epitope clusters with significant cluster scores10 were identified. Three peptides (aa 32–50, 
100–118, and 190–209) were excluded from further study, as they had three of the four 
lowest cluster scores; two additional peptides (aa 73–96 and 176–198) were not selected for 
synthesis due to high hydrophobicity. The informatics analysis was repeated on the 
remaining six putative epitopes in 2010 with a revised version of the EpiMatrix algorithm, 
which had been retrained on a more robust set of epitopes using the expanded set of 
sequences available in 2009. This updated matrix is improved relative to the 2002 matrix 
and has demonstrated greater accuracy when benchmarked against other prediction 
tools.11,12 From the six putative epitopes previously identified, three peptides: C3d223–246, 
C3d248–265, and C3d269–286 were selected for further study based on their updated 
EpiMatrix scores, broad binding to a range of HLA in competition binding assays, and 
ability to induce IFNγ responses in non-HLA typed donors (see ref. 9 and Table 1). All three 
clusters are distributed in Region 2 (aa 175–290) of C3d; notably, C3d223–246 overlaps with 
the C3d peptide fragment P28 (aa 208–235), identified by Lambris et al.,13 by 13 amino 
acids (Figure 1).
HLA binding validates in silico predictions
Class II HLA binding assays were conducted to validate the in silico EpiMatrix predictions, 
as described in Methods. Each of the C3d epitope peptides bound to at least one of the six 
different HLA DR alleles tested with high affinity (see Table 2). Peptide C3d223–246 bound 
with high affinity to four alleles (0101, 0401, 0701, 1101), moderate affinity to one allele 
(0301), and weak affinity to one allele (1501). Peptide C3d269–286 bound with high affinity 
to four alleles (0101, 0401, 0701, 1101) and weak affinity to two alleles (0301, 1501). 
Peptide C3d248–265 bound with high affinity to one allele (1101) and did not bind to the 
other five alleles tested. For greater than two-thirds of the peptide/HLA allele combinations, 
binding results confirmed EpiMatrix predictions (Table 2). Comparison of HLA binding 
results to our earlier work reveals some discrepancies with those found in current studies 
due to a number of modifications to the assay to improve robustness and sensitivity over 
time. This includes the use of peptides capped at their N- and C-termini to improve peptide 
stability, which likely contributed to improved binding affinity among predicted peptides 
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that were non-binders in our earlier work (e.g., peptides C3d223–246 and C3d269–286 had high 
cluster scores but either did not bind or bound only weakly to 0101 and 0701 in the previous 
study, but both peptides had improved binding affinity to these alleles once capped). 
Furthermore, optimizations were introduced to increase signal-to-noise ratios; as a result, 
peptides that had previously bound weakly, possibly due to an initial high background 
producing a false positive signal (e.g. C3d248–265 binding with high affinity to 1501 in the 
previous work), exhibited weak or no detectable binding in the improved assay. Finally, the 
use of an updated, more accurate EpiMatrix algorithm in the current study led some peptides 
that were previously predicted to bind given HLA alleles to be re-classified as non-binders 
(e.g., C3d248–265 was originally predicted to bind 1501, but its updated EpiMatrix score 
classifies it as a non-binder for this allele, which corresponds to the negative binding results 
in vitro). Comparison of the results in this work to previous studies reveals improved 
correlations between in silico predictions and in vitro binding (83% correlation in this work 
vs. 50% correlation in earlier work), which we attribute to these assay improvements and 
use of the improved EpiMatrix algorithm.
C3d epitopes induce IFNγ responses from multiple donors
To confirm observations from HLA binding assays and correlate C3d-specific T cell 
responses to HLA background, we stimulated PBMCs from HLA-typed donors and tested 
for cytokine responses to C3d peptides by IFNγ ELISpot. PBMCs from four healthy donors 
were stimulated with a C3d peptide pool (comprised of C3d223–246, C3d248–265 and 
C3d269–286) or an irrelevant peptide (Pan-DR epitope; PADRE) for 10 days to expand the 
number of C3d-specific T cells from baseline. Harvested PBMCs were then re-stimulated 
with the C3d peptide pool, individual C3d peptides, PADRE, PHA (positive control), or no 
peptide. ELISpots were used to determine IFNγ secretion two days after re-stimulation. 
Each plot in Figure 2 shows IFNγ responses from one of four donors to each stimulation 
condition. As shown in Figure 2, most of the donors responded specifically to at least one 
C3d peptide, and all donors responded to the C3d peptide pool. No response was seen to 
these same peptides when donor cells were initially cultured with PADRE and then 
restimulated with C3d peptides. In most cases, ELISpot responses correlate well with 
EpiMatrix predictions and HLA binding. For example, Subject 666 (HLA DRB1*0701) 
responded strongly to C3d223–246 and C3d269–286 as predicted by EpiMatrix and as observed 
by HLA binding assay specifically for this donor’s HLA allotype (see Table 2, Figure 2A). 
Additionally, a response was observed for all three C3d peptides, including C3d248–265, for 
Subject 705. The HLA type of this donor (HLA DRB1*1101) matches the only allele 
predicted and observed to bind this peptide in HLA binding assays (Table 2, Figure 2C). 
Subject 703, with HLA DRB1*0301 (Figure 2D), generated a low response to C3d223–246 
and to the C3d peptide pool. Again, this result corresponds to the binding data; HLA 
DRB1*0301 only moderately bound C3d223–246, and only weakly bound or did not bind 
C3d269–286 and C3d248–265, respectively (Table 2). The only discordance observed with 
HLA binding was in Subject 706 (HLA DRB1*0401), who responded strongly to 
C3d223–246 as predicted and observed for HLA binding, but did not respond significantly to 
C3d269–286 (Table 2, Figure 2B).
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Responses to C3d peptides are generated by CD4+ memory T cells in the periphery
In our previous work, we used immunophenotyping and fluorescence-activated cell sorting 
(FACS) to demonstrate that the IFNγ response to C3d peptides was primarily generated by 
CD4+ cells.9 To extend this observation and confirm that C3d-specific CD4+ T cells also 
express cell surface markers characteristic of memory T cells (providing support for our 
hypothesis that C3d-specific memory T cells circulate in the periphery), we repeated the 
FACS assay with additional immunophenotyping to determine whether the C3d-specific 
response was due to naïve or memory T cells. A representative experiment is shown in 
Figure 3, in which PBMCs stimulated with a C3d peptide pool at a total concentration of 30 
µg/ml or with MOG35–55 (negative control peptide) at 30 µg/ml were cultured for 10 days. 
Similar to C3d epitopes, MOG35–55 is an autologous T cell epitope that binds multiple HLA 
types.14 While MOG35–55 is an auto-antigen in multiple sclerosis, the peptide does not 
induce an immune response in healthy individuals. On day 10, PBMCs were stimulated with 
the C3d peptide pool, MOG35–55, the polyclonal stimulator CytoStim (Miltenyi), or media 
alone for three hours. After three hours of secondary stimulation, IFNγ-positive cells were 
enriched using an IFNγ secretion assay kit (Miltenyi), stained with antibodies for CD4, 
CD45RA (naïve marker) and CD45RO (memory marker), and analyzed by flow cytometry. 
We gated first on CD4+, IFNγ+ cells and then on the CD45RA and CD45RO populations.
As shown in Figure 3, memory (CD4+IFNγ+CD45RO+) T cells are the dominant 
population responding to the C3d peptides in this assay system. A mixed naïve (CD4+ IFNγ
+CD45RA+) and memory (CD4+IFNγ+CD45RO+) response was generated to CytoStim, 
indicating naïve T cells could be re-stimulated under these conditions. This is in contrast to 
the negative control peptide, MOG35–55, which did not induce an autoreactive memory (or 
naïve) T cell response. These results suggest that T cell responses are specific to C3d, are 
not seen in response to other autologous peptides (in healthy control subjects), and are 
mediated by autoreactive memory T cells circulating in the periphery.
Disruption of the single T cell epitope in P28 diminishes the activity of C3d in vivo
It has been proposed that the adjuvant effect of C3d involves interaction between BCR:anti-
polysaccharide and C3d:CD21, lowering the threshold of B cell activation by engaging 
CD19 with Igα/β.15,16 While the P28 peptide segment (amino acids 208–235of C3d) has 
previously been implicated as mediating C3d binding to CD2113,17,18, this role has been 
disputed based on the 2011 crystal structure of C3d interacting with CD21.19 Rather, the 
finding that the P28 segment harbors a T cell epitope provides support for the reported 
adjuvant properties of P28, whether or not it is involved in mediating binding to CD21. The 
adjuvant activity of multiple copies of P28 has been established in the context of protein 
immunogens20 and DNA vaccine immunogens.5 Indeed, a 4X repeat of the P28 peptide 
segment retains equal adjuvant activity to a 3X repeat of full-length C3d when delivered as a 
recombinant DNA vaccine with the HIV-1 ENVgp120 glycoprotein.5 An EpiMatrix analysis 
of the P28 peptide segment revealed a single promiscuous HLA binding motif located at the 
C-terminus of P28 (Figure 4). Interestingly, this single T cell epitope overlaps with the N-
terminal T cell epitope in the C3d223–246 epitope cluster described in this work, which is 
shown to bind multiple HLA alleles in vitro and to induce IFNγ responses in multiple 
donors (Table 2, Figures 1 and 2). We hypothesized that if the adjuvant activity of P28 is 
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abolished or diminished due to mutation of this single T cell epitope, it would help explain 
the adjuvant activity of P28.
Using EpiMatrix, we selected two variants of the T cell epitope in the P28 peptide segment 
which were designed to disrupt HLA binding to eight of the most common HLA types 
(covering >90% of human populations) and mouse MHC alleles(Figure 4). The first 
modification (P28Mod1) was predicted to disrupt recognition by most HLA types and 
murine MHC alleles, and the second, more aggressive modification (P28Mod2) was 
predicted to fully disrupt recognition by all HLA types and murine MHC alleles. Amino acid 
modifications selected for each variant have been previously made and shown to have no 
effects on CD21 binding, effectively decoupling the impact of mutagenesis on epitope:MHC 
interactions from epitope:CD21 binding.18 Our group recently published work on the 
implementation of such methods to deimmunize Factor VIII (FVIII), in which we predicted 
and observed changes in immune responses to the modified FVIII epitopes for humanized 
mice and for FVIII-deficient mice.21
In HLA binding assays, deimmunizing modifications to the peptide representing the specific 
region where the P28 peptide segment overlaps with C3d223–237 reduced peptide binding to 
the DRB1*0101 and 0401 alleles in comparison with the corresponding wild type sequence 
(Table 3). These results suggest that the peptide mutations may also disrupt binding to 
mouse MHC and reduce antigenicity of P28.
A recombinant expression construct corresponding to the HIV-1 ENVgp120 glycoprotein 
antigen fused to a 4X repeat of P28 or “deimmunized” P28Mod1 or P28Mod2 was created 
for in vivo expression and analysis of adjuvant activity.
Six- to eight-week-old BALB/c mice received 5 µg of DNA by intramuscular gene gun 
delivery encoding ENVgp120-4XP28, ENVgp120-4XP28Mod1, and 
ENVgp120-4XP28Mod2on weeks 0, 3, and 6. At week 8, blood was collected, and ENVgp120 
titers were measured by enzyme-linked immunosorbent assay(ELISA). Figure 5 shows that 
while immunization with ENVgp120 glycoprotein recombinantly expressed with wild-type 
P28 contributed to robust immune responses as measured by anti-ENVgp120 antibody titers, 
immune responses to ENVgp120 were significantly diminished when recombinantly 
expressed with either of the P28 deimmunized modifications (P28Mod1 and P28Mod2). In 
fact, a further-diminished immune response was observed with P28Mod2, the more 
aggressive mutation predicted to more effectively disrupt recognition by both I-Ad and I-Ed. 
The results of this experiment suggest that the adjuvant activity of P28 may involve MHC 
binding and T cell epitope content, providing in vivo evidence for T cell mediated 
immunogenicity in the adjuvant activity of C3d.
DISCUSSION
Adjuvants consisting of a polysaccharide antigen covalently linked to either a foreign carrier 
protein or to complement component C3d often enhance the generation of a primary 
humoral response.1,2,3 The prevailing model suggests the adjuvant effect of C3d is due to B 
cell activation upon cross-linking of the antigen recognition molecules (Ig) and complement-
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binding molecules (CD21), resulting in a lowered activation threshold and more robust 
immune response.4,15 Yet mice lacking complement receptors CD35 (CR1) and CD21 
(CR2) were observed to respond to protein antigen-C3d conjugates in a similar or enhanced 
manner, respectively, as compared to wild-type mice6,7 These findings challenge the current 
models and suggest an auxiliary immune activation pathway. We thus propose a second 
component to the adjuvant effect of C3d: namely, that C3d is rich in T cell epitopes and that 
when, in the course of antigen internalization and processing, they are presented by MHC II 
to autoreactive T helper cells, this T cell help enhances antibody responses. In earlier work, 
we showed that C3d contains an unusually high concentration of T cell epitopes compared 
to other serum proteins, suggesting that T cell activation by MHC display of C3d epitopes 
may be an alternative mechanism for adjuvant activity of C3d.
In the present study, we provide evidence for the role of T cell epitope content and 
autoreactive T cells in the development of immune responses to C3d and associated 
antigens. Focusing on three peptides identified in our previous work,9 we establish that C3d 
epitope-specific responses (as judged by IFNγ ELISpot) are apparent in multiple donors and 
furthermore, donors respond to peptides in a manner consistent with HLA type as predicted 
by in silico methods and in vitro HLA binding assays (Table 2, Figure 2). The prior studies 
were conducted with non-HLA typed donors and HLA binding was performed with fewer 
alleles, preventing the correlations established in this work.
To further test the relative contribution of T cell epitopes to the adjuvant effect of C3d, we 
focused on the P28 peptide segment of C3d. P28 is an attractive candidate for 
deimmunization since it has a single T cell epitope (overlapping with the C3d223–246 epitope 
cluster identified in our studies) and has demonstrated adjuvant properties in the context of 
protein immunogens20 and DNA vaccine immunogens.5 By mutating this single T cell 
epitope, we effectively demonstrate the importance of T cell epitope content to the adjuvant 
activity of C3d. Our finding that targeted mutations to P28, predicted to disrupt MHC 
recognition (Figure 4) and significantly decreasing the adjuvant activity of P28 in vivo 
(Figure 5), supports the role that T cell epitope content may have in C3d adjuvant activity.
Regions of C3d encompassing predicted T cell epitopes appear to be highly conserved 
throughout evolution of multicellular phyla - further highlighting their critical biological 
function (Matthew Ardito, personal communication).A better understanding of the 
biological role of these epitopes as undertaken in this study and careful evolutionary 
mapping may place C3d at a critical evolutionary junction where humoral immunity meets 
cellular responses. In fact, components of complement have been shown to be expressed by 
dendritic cells (critical for cellular immunity) and have further been shown to be necessary 
for T cell activation.22,23 We believe this activation to be in part due to MHC presentation of 
C3d epitopes.
Focusing on the T cells responding to these epitopes, immunophenotyping of the C3d 
epitope-activated T cells points to a prominent role for CD4+CD45RO+ memory T cells 
circulating in the periphery in this response (Figure 3). Thus it appears that C3d-specific 
autoreactive T cells are circulating in the periphery, poised to respond to C3d associated 
with foreign antigens. While there are numerous examples of unwanted responses by 
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autoreactive T cells in such autoimmune diseases as type 1 diabetes,24 rheumatoid 
arthritis,25 and multiple sclerosis,26 these data suggest a natural, beneficial role for 
autoreactive T cells. A link between activation of complement and antibody-associated 
autoimmune disorders such as uveoretinitis and Systemic Lupus Erythematosis has been 
described.27,28 Additionally, it is known that thymic deletion of autoreactive T cells is 
imperfect; 25–40% of autoreactive T cells escape into the periphery because of low TCR 
avidity,29,30 absence of antigen expression in the thymus, inefficient expression, or 
inefficient processing.31 This escape of autoreactive T cells to the periphery may indicate a 
need for them in natural immunity.
We have used our immunoinformatics tools to identify other T cell epitopes in autologous 
proteins that suppress immune response. Using EpiMatrix and ClustiMer, we discovered 
regulatory T cell epitopes (Tregitopes) that reside within IgG and likely within other 
autologous, high-abundance serum proteins, pointing to a very different role for Tregitope-
autoreactive T cells -- in this instance, induction of natural Tregs and tolerance to associated 
antigenic epitopes.32 Tregitopes may serve to dampen immune response to co-administered 
immunogens (such as antibody idiotypes). In contrast to Tregitopes, which may serve as a 
universal “off switch,” our data would indicate that C3d induces an effector response to 
associated epitopes, acting as a universal “on switch.”
A better understanding of the C3d-specific T cell responses observed here may lead to an 
enhanced knowledge of the role of complement in autoimmune disorders, as well as the role 
of autoreactive T cells in autoimmune disease and natural defense mechanisms. Our findings 
are consistent with the existence of a CD21-independent pathway by which peripheral T 
helper cells are activated by self peptide-MHC II complexes, aiding in the adjuvant effect of 
C3d opsonization, and perhaps representing a critical link between humoral and cellular 
responses to foreign antigens.
MATERIALS AND METHODS
Immunoinformatics
T cell epitopes in human C3d were identified using the epitope-mapping algorithm 
EpiMatrix.33 Updated cluster scores are referenced in this work. The 302-amino-acid 
sequence was parsed into overlapping 9-mer frames, each of which was analyzed against a 
panel of eight common HLA class II alleles that cover >90% of human populations 
(DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, DRB1*1101, 
DRB1*1301, and DRB1*1501).34 From this EpiMatrix analysis, 11 “clusters,” or regions of 
high putative T cell epitope content, were identified, of which three candidates (17–23 
amino acids in length) were chosen for synthesis. In-depth discussion of the methods used 
for making predictions with EpiMatrix can be found in De Groot et. al.35 Frames are given 
Z-scores, which range from approximately −3 to +3 and are normally distributed. These 
scores indicate the potential of a 9-mer frame to bind to a given HLA allele. Frames 
containing four or more alleles scoring above 1.64 are referred to as EpiBars, and have an 
increased likelihood of binding to HLA. Significant EpiMatrix scores across multiple frames 
are then aggregated to create an EpiMatrix Cluster Immunogenicity score. Epitope clusters 
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identified in reference 9 using EpiMatrix version 1.1 were re-analyzed in the updated 
version 1.2. Updated cluster scores are referenced for this work in Table 1.
Peptide synthesis
Peptide synthesis was conducted (21st Century Biochemicals; Marlboro, MA, USA) using 
solidphase peptide synthesis employing N-(9-fluoronylmethoxycarbonyl) (Fmoc)-based 
chemistry and Fmoc-L-amino acid building blocks on an automated Rainin Symphony-
Protein Technologies synthesizer to >80% purity. Peptides were synthesized with the amino 
and carboxyl ends blocked to reduce peptide degradation during incubations. Peptide 
sequence and purity was confirmed by MALDI/TOF MS on a QSTAR XL Pro mass 
spectrometer. The peptides selected for this study (located at amino acids 223–246, 248–
265, and 269–286 of the C3d sequence) were based on EpiMatrix analyses described above 
(see Table 1).
HLA binding assays
Each of the three C3d peptides was tested in HLA binding assays to six alleles: 
DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, and DRB1*1501. Class 
II HLA binding assays were adapted for high throughput by EpiVax from methods 
previously described by Kwok and colleagues.36 Non-biotinylated test peptide over a range 
of concentrations (2–128 µM) competed against a biotinylated tracer peptide (0.1–1 µM) for 
binding to purified class II HLA molecules (0.5–2 µg/ml) in 96-well plates at 37°C for 24 
hours. Pan anti-class II antibodies (L243, anti-HLA-DR) were used to capture class II 
complexes on ELISA plates, which were developed using streptavidin-europium and read on 
a time-resolved fluorescence plate reader. Nonlinear regression analysis was performed, and 
half maximal inhibitory concentrations (IC50) values were calculated.
Blood samples
Interferon gamma ELISpot assays were performed using cryopreserved peripheral blood 
mononuclear cells (PBMCs) separated by Ficoll density gradient centrifugation of whole 
blood. Healthy human subjects were recruited from Clinical Partners in Johnston, RI, USA 
in accordance with all federal guidelines and institutional policies. Institutional review 
boards in Providence, RI approved the informed consent procedures and research protocols. 
Informed consent was obtained prior to obtaining all samples for this study.
ELISpot assays
Cryopreserved PBMCs from four healthy human donors with HLA types DRB1*0301, 
DRB1*0401, DRB1*0701, and DRB1*1101 were used to determine the frequency of 
epitope-specific T lymphocytes. Purified PBMCs were stimulated on day 1 with either pan 
HLA DR-binding epitope (PADRE) or a pool of three C3d-derived peptides at a final total 
peptide concentration of 30 µg/ml in RPMI 1640+GlutaMax (Life Technologies; Grand 
Island, NY, USA) supplemented with 10% human AB serum (Valley Biomedical; 
Winchester, VA, USA), 1% L-glutamine (Life Technologies), 1% 1M HEPES (Life 
Technologies), and 50 µg/ml Gentamycin (Sigma-Aldrich; St. Louis, MO, USA). Cells were 
plated at 5 million cells per well in a 12-well plate and incubated for 10 days at 37°C and 
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5% CO2. IL-2 (10 ng/ml) and IL-7 (20 U/ml), both manufactured by BioSource (Nivelles, 
Belgium), were added to each of the wells on days 1 and 5 of the incubation period, and a 
half-medium exchange was performed on day 5. On day 10, PBMCs were harvested and 
added at 2.5 × 105 cells per well to a Mabtech® IFNγ ELISpot plate pre-coated with anti-
IFNγ antibody (Mabtech; Nacka, Sweden). Cells were re-stimulated in triplicate in the 
ELISpot plate with 10 µg/ml of one of the three individual C3d peptides, 30 µg/ml of 
PADRE, 30 µg/ml of the C3d peptide pool, or 2 µg/ml PHA (positive control).Twelve wells 
of cells without re-stimulation were used to measure assay background. Plates were 
incubated at 37°C and 5% CO2 for 48 hours and were developed according to the 
manufacturer’s instructions. To develop, plates were washed and biotinylated anti-IFNγ was 
added; after a two hour incubation, plates were washed again, and streptavidin-HRP was 
added. Plates were incubated for one hour, washed, and developed by addition of TMB 
substrate. The frequency of antigen-specific cells was calculated as the number of spots per 
106 cells seeded. Responses were considered positive if the number of spots was 
significantly greater by Student’s t-test than 50 spot forming cells per well (1 spot over 
background per 20,000 PBMCs).
Immunophenotyping
PBMCs from a single DRB1*0701-positive donor (Clinical Partners; Johnston, RI, USA) 
were stimulated with a C3d peptide pool (comprised of C3d223–246, C3d248–265, and 
C3d269–286) at 30 µg/ml or with MOG35–55 peptide at 30 µg/ml for 10 days under the same 
conditions as the ELISpot preculture. On day 10, PBMCs were stimulated with the C3d 
peptide pool, MOG35–55, CytoStim (Miltenyi Biotec; Bergisch Gladbach, Germany), or 
media alone for three hours. After secondary stimulation, IFNγ-positive cells were enriched 
using an IFNγ secretion assay kit (Miltenyi) and then co-stained with anti-human antibodies 
for CD4-FITC, CD45RA-PerCP, and CD45RO-APC, according to the manufacturer’s 
recommendations (eBioscience; San Diego, CA, USA). Samples were acquired on a 
Beckton Dickinson FACSCalibur flow cytometer. In FlowJo analysis software, CD4+, IFNγ
+ cells were identified from the live lymphocytes, and proportions of CD45RA+ and 
CD45RO+ cells were examined within this double-positive population.
Mouse studies
BALB/c mice (Mus musculus, female, 6–8 weeks) were purchased from Harlan Sprague 
Dawley (Indianapolis, IN, USA), housed in microisolator units with free access to food and 
water, and cared for under USDA guidelines for laboratory animals. Mice (n=5 per group) 
were gene gun-immunized on shaved abdominal skin using the hand-held Bio-Radgene 
delivery system. Mice were immunized with two gene gun doses (at weeks 0, 3 and 6) 
containing 5 µg of DNA (encoding ENVgp120-4xP28, ENVgp120-4xP28Mod1, or 
ENVgp120-4xP28Mod2) per 0.5 mg of approximately 1 µm gold beads (Bio-Rad; Hercules, 
CA, USA) at a helium pressure setting of 400 lb/in2. Fourteen days after the third 
vaccination (week 8), blood was collected from anesthetized mice via the retro-orbital 
plexus and transferred to a microfuge tube. For blood sample collection, animals were 
anesthetized with a mixture of ketamine/xylazine. Tubes were centrifuged, and sera was 
removed and frozen at −20 ± 5°C. ENVgp120 antibody titers were measured by ELISA. 
P28Mod1 alone was used as a negative control, and codon optimized gp120 (cogp120), 
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which expresses 7–10 times more gp120 protein than wtgp120 at the same DNA dose37, was 
used as a positive control. For data processing, the single highest responding mouse in every 
group was removed from analysis. All procedures were in accordance with the NRC Guide 
for the Care and Use of Laboratory Animals, the Animal Welfare Act, and the CDC/NIH 
Biosafety in Microbiological and Biomedical Laboratories.
ELISA
The ELISA was used to assess total antibody titer to the HIV-1 envelope. High-binding, 96-
well polystyrene plates (Costar; Lowell, MA, USA) were coated overnight with 50 ng/well 
of recombinant ENV. Plates were blocked with 5% milk diluted in PBS with 0.05% Tween 
20. Serum samples were diluted in blocking buffer and added to plates. Serum was two-fold 
serially diluted and allowed to incubate for 1 hour at room temperature. Plates were washed, 
and horseradish peroxidase (HRP)-linked species-specific antibody against IgG was diluted 
in blocking buffer and added to plates. Plates were incubated for 1 hour at room 
temperature. Plates were washed, and HRP was developed with TMB substrate (Sigma-
Aldrich). Plates were incubated in the dark for 15 minutes, and then the reaction was 
stopped with 2N H2SO4. Optical densities at a wavelength of 450nm (OD450) were read by a 
spectrophotometer (BioTek; Winooski, VT, USA), and endpoint dilution titers were 
determined as the reciprocal dilution of the last well which had an OD450 above the mean 
OD450 plus two standard deviations of naïve animal sera.
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Figure 1. The T cell epitope region of C3d residues 223–246 overlaps with P28
The T cell epitope shared between P28 and C3d223–246 is shown in bold. Amino acids in 
italics and underlined were mutated. Solid underline denotes amino acids mutated to alanine 
in P28Mod1. The additional K>N mutation in P28Mod2 is denoted by the dotted underline. 
The P28 region, which contains the major binding site of C3d to CD21,13 shares 13 amino 
acids with C3d.
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Figure 2. PBMCs from healthy donors respond specifically to C3d epitope clusters
Frozen PBMC samples from four healthy donors (A–D) were thawed and stimulated for 10 
days with either a pool of human C3d epitope peptides or a non-specific control peptide, 
PADRE. Cells were re-stimulated in a 48-hour IFNγ ELISpot with either individual peptides 
or pools. A response was considered positive if the number of spots was greater than or 
equal to 50 spot forming cells over background per 106 PBMCs. HLA type of donors is 
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shown at the top of each graph. PBMCs from all donors responded to C3d peptides when 
cultured with the C3d peptide pool.
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Figure 3. C3d epitopes specifically induce a memory T cell response
Primary stimulations were performed as in Figure 2. Secondary stimulations with media, 
C3d peptide pool, MOG35–55 or CytoStim (Miltenyi) were performed for three hours. IFNγ-
secreting cells were then captured, magnetically separated (Miltenyi) and labeled with 
antibodies for CD4, CD45RA (naïve marker) and CD45RO (memory marker). Cells were 
first gated for CD4+IFNγ+, then CD45RA and CD45RO. Each primary stimulation group 
above is subtracted for background with secondary stimulation of media alone. Incubation 
and re-stimulation with the C3d peptide pool produced a significant increase in the 
CD4+IFNγ+CD45RO+ memory T cell subpopulation.
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Figure 4. Targeted mutation of the single T cell epitope in P28 abolishes predicted binding to 
HLA and MHC alleles
EpiMatrix cluster reports show the P28, P28Mod1 and P28Mod2 sequences parsed into 
overlapping 9-mer frames. Each 9-mer is analyzed for predicted recognition by eight 
common HLA haplotypes and MHC alleles I-Ab, I-Ad and I-Ed. Z-Scores above 1.64 are 
predicted to bind respective alleles. Epitope/HLA matches are shown in shaded boxes. 
Modified amino acids in P28Mod1 and P28Mod2 are underlined. The P28Mod1 variant is 
predicted to disrupt binding to most MHC alleles, and the more aggressive P28Mod2 variant 
is predicted to fully disrupt binding.
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Figure 5. Mutation of the single T cell epitope in P28 significantly diminishes its adjuvant 
activity
The immunogenicity of wild-type gp120 (wtgp120; open circles) is enhanced when 
conjugated to a 4X concatamer of P28 (wtgp120-p28; black circles) as measured by anti-
Env titers. When conjugated to a 4X concatamer of P28 mutated at the single predicted T 
cell epitope (wtgp120-p28mod1, wtgp120-p28mod2; open squares and black squares, 
respectively) the adjuvant activity of P28 is significantly diminished. P28mod1 alone was 
used as a negative control. Codon optimized gp120 (cogp120), which expresses 7–10 times 
more gp120 protein than wtgp120 at the same DNA dose37, was used as a positive control. 
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Immunization with ENVgp120 glycoprotein conjugated to p28mod1 or p28mod2 
significantly diminished antibody responses.
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Table 1
C3d peptide locations, sequences, and cluster scores
Amino acids were numbered according to their position within C3d (N terminus to C terminus); position 1 of 
C3d corresponds to position 1002 of C3. EpiMatrix cluster scores are a measure of epitope promiscuity 
(probability to be recognized by multiple HLA alleles). Potentially immunogenic epitopes tend to have higher 
EpiMatrix cluster scores.
Peptide
name
Start and stop in
mature C3d
Equivalent start
and stop in C3
Sequence EpiMatrix
cluster score
C3d223–246 223–246 1224–1247 GKQLYNVEATSYALLALLQLKDFD 7.12
C3d248–265 248–265 1249–1266 VPPVVRWLNEQRYYGGGY 6.24
C3d269–286 269–286 1270–1287 QATFMVFQALAQYQKDAP 23.01
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Table 2
EpiMatrix predictions correlate well with in vitro HLA binding
Peptides were predicted to bind a given HLA allele if their EpiMatrix Z-score was >1.64. Binding results that 
differ from predicted results are in parenthesis. Binding results confirmed EpiMatrix predictions for 83% of 
the peptide/HLA allele combinations.
Peptide
name
HLA-DRB1 Allele EpiMatrix Z-score Prediction Binding IC50
(µM)
C3d223–246
0101 1.75 binder <2
0301 1.65 binder 13.96
0401 2.37 binder <2
0701 1.62 non-binder (<2)
1101 1.96 binder <2
1501 1.92 binder 85.07
C3d248–265
0101 1.90 binder (non-binder)
0301 1.80 binder (non-binder)
0401 1.63 non-binder non-binder
0701 0.72 non-binder non-binder
1101 2.28 binder <2
1501 1.35 non-binder non-binder
C3d269–286
0101 1.69 binder 5.63
0301 1.72 binder 77.63
0401 2.68 binder 9.64
0701 1.70 binder 2.45
1101 2.37 binder <2
1501 2.43 binder >100
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Table 3
HLA binding of the single T cell epitope in P28 and its deimmunized variants
HLA binding was assessed for the sequence overlapping the P28 peptide segment and C3d223–237 (Figure 1) 
and two variants designed to disrupt binding. Assays were performed for HLA alleles predicted to bind the 
wild type sequence. Modified amino acids in peptide sequences are underlined and in bold. Binding affinities 
are expressed as IC50 values in nM. The variant (MOD1 and MOD2) mutations reduced peptide binding to 
HLA DRB*0101 and *0401, as indicated by higher IC50 values.
Peptide Sequence,
C3d223–237
Binding IC50 Values (nM) by HLA Allele
DRB1*01:01 DRB1*03:01 DRB1*04:01
WT: GKQLYNVEATSYALL 365 2396 170
MOD1: GKQAANVEATSYALL 582 2873 5202
MOD2: GNQAANVEATSYALL 992 1208 4407
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